Gene therapy for gp91 gene defects delivered with a retroviral vector: Phase I/II

VMRX said that CD34 stem cells transfected with a corrected copy of the defective gene that were given to patients allowed production of normal white blood cells for >6 months in an ongoing Phase I/II trial. ...